Targeting human plasmacytoid dendritic cells through BDCA 2

Targeting human plasmacytoid dendritic cells through BDCA 2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma by Rebecca L Ross, Clarissa Corinaldesi, Gemma Migneco, Ian M Carr, Agne Antanaviciute, Christopher W Wasson, Antonio Carriero, Jörg H W Distler, Steve Holmes, Yasser M El-Sherbiny, Clive S Mc. Kimmie, and Francesco Del Galdo Ann Rheum Dis Volume (): annrheumdis-2020 -218439 February 4, 2021 © 2021 by BMJ Publishing Group Ltd and European League Against Rheumatism

TLR 9 -induced activation of human p. DC goes beyond type I IFN secretion and is hindered by BDCA 2 -targeting in vitro. Rebecca L Ross et al. Ann Rheum Dis doi: 10. 1136/annrheumdis-2020 -218439 © 2021 by BMJ Publishing Group Ltd and European League Against Rheumatism

Human p. DC induced IFN response in OSR, which is suppressed by BDCA 2 -targeting. Rebecca L Ross et al. Ann Rheum Dis doi: 10. 1136/annrheumdis-2020 -218439 © 2021 by BMJ Publishing Group Ltd and European League Against Rheumatism

Xeno. SCID with human p. DC increased skin IFN response to TLR stimulation in a BDCA 2 dependent manner. Rebecca L Ross et al. Ann Rheum Dis doi: 10. 1136/annrheumdis-2020 -218439 © 2021 by BMJ Publishing Group Ltd and European League Against Rheumatism

Xeno. SCID with human p. DC increased the pro-fibrotic skin response to bleomycin treatment in a BDCA 2 -dependent manner. Rebecca L Ross et al. Ann Rheum Dis doi: 10. 1136/annrheumdis-2020 -218439 © 2021 by BMJ Publishing Group Ltd and European League Against Rheumatism